Update date: February 1, 2024

Group No. 4: Dermatology

SWEET ALMOND OIL

Clue	Description	Indications	Route of administration and dosage
	CREAM Sweet almond oil, lanolin, glycerin, propylene glycol, sorbitol.	Contact dermatitis.	Cutaneous. Adults and children: Apply to all affected skin as many times as necessary.
010.000.0910.00	Container with 235 mL.		
	CREAM Sweet almond oil and calcium hydroxide.		
010.000.2118.00	Container with 240 mL.		

Generalities

Emollient and moisturizing on the skin.

Risk in Pregnancy TO

Adverse effects

None.

Contraindications and Precautions

None.

Interactions

None of clinical importance.

ADALIMUMAB ***(In prescription control program)***

Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION Each vial or prefilled syringe or prefilled syringe in autoinjector with 0.8 mL contains: Adalimumab 40 mg	Rheumatoid arthritis with inadequate response to Traditional DMARDs. Psoriasic arthritis. Ankylosing spondylitis.	Subcutaneous. Adults: Rheumatoid arthritis: 40 mg every 15 days. In combination with methotrexate.
010.000.4512.00	Package with a prefilled syringe.	Crohn's disease.	Psoriatic arthritis and ankylosing spondylitis: 40 mg every 15 days.
010.000.4512.01	Container with a vial and syringe.	Psoriasis.	Active Cronhn's disease: Induction: 160mg; apply 4 doses of 40 mg per day on two consecutive days, followed by 80 mg, two weeks later (day 16).
010.000.4512.02	Package with a prefilled syringe in autoinjector. Each 0.4 mL prefilled syringe or prefilled pen contains: Adalimumab 40 mg		Maintenance: Two weeks after finishing the induction period (day 30); apply 40 mg per day, every 2 weeks. Psoriasis:
010.000.4512.03	Pack with a prefilled syringe or prefilled pen		Plaque psoriasis, of moderate to severe intensity, apply 80 mg/day, followed after 7 days by 40 mg/day and then 40 mg every two weeks.

Generalities

It blocks the action of tumor necrosis factor-alpha, a molecule that causes inflammation and destruction of joints.

Risk in Pregnancy C

Adverse effects

Rhinitis, sinusitis, bronchitis, pneumonia, urinary tract infections, stomatitis, myalgia.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug, pregnancy, lactation, tuberculosis, multiple sclerosis.

Interactions

None of clinical importance.

ALLANTOIN AND COAL TAR

Clue	Description	Indications	Route of administration and dosage
	DERMAL SUSPENSION Each mL contains: Allantoin 20.0 mg. Coal tar 9.4 mg. Container with 120 mL.	Psoriasis.	Cutaneous. Adults and children: Apply every 12 hours on affected areas Maintenance: apply 2 to 3 times a week.
010.000.0831.00			

Generalities

Keratoplastic and keratolytic and antipruritic action.

Risk in Pregnancy

TO

Adverse effects

Overuse erythema, contact dermatitis and photosensitivity.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug and abraded skin.
Precautions: Avoid contact with eyes.

Interactions

None of clinical importance.

ALLANTOIN, COAL TAR AND CLIOQUINOL

Clue	Description	Indications	Route of administration and dosage
	CREAM Each 100 grams contain: Allantoin 0.2 g. Coal tar solution 5.0 g. Clioquinol 3.0 g. Container with 60 g. Container with 150 g.	Psoriasis. Seborrheic dermatitis.	Cutaneous or scalp. Adults: Apply an adequate amount to the psoriatic lesion or scalp, twice a week.
010.000.5132.00 010.000.5132.01			

Generalities

Synergistic combination with keratolytic, keratoplastic, epithelializing, photosensitizing, antiseptic and antipruritic action.

Risk in Pregnancy

b

Adverse effects

Local itching and burning.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug.
Precautions: Avoid contact with eyes.

Interactions

None of clinical importance.

ALIBOUR

Clue	Description	Indications	Route of administration and dosage
	DUST Each gram contains: Copper Sulfate 177.0 mg. Zinc Sulfate 619.5 mg. Camphor 26.5 mg. Container with 12 sachets with 2.2 g.	Pyodermitis. Impetiginized dermatoses. Exfoliative dermatitis.	Cutaneous. Adults and children: Apply peeling agents every 8 to 24 hours.
010.000.0871.00			

Generalities

Its absorption through the skin helps to regenerate damaged tissues.

Risk in Pregnancy

TO

Adverse effects

Drug hypersensitivity, irritation, contact dermatitis.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug.

Interactions

None of clinical importance.

COLLOID BATH

Clue	Description	Indications	Route of administration and dosage
	DUST Each gram contains: Soy flour 965 mg. (protein content 45%). Polyvidone 20 mg.	Dermatitis	Cutaneous. Adults: Dissolve one sachet in the bathtub water. Stay in the water for 15 to 20 minutes, every 12 to 24 hours.
010.000.0801.00	Packaging with an individual 90 g sachet.		For limited regions: Dissolve two tablespoons of powder in 4 liters of warm water. Apply every 8 to 12 hours.
010.000.0801.01	Package with two individual 90 g sachets.		Children: Dissolve 2 or 3 tablespoons in the bath water. Let the solution be in contact with the skin for 20 minutes.

Generalities

It produces symptomatic relief from the discomfort caused by acute dermatitis, especially itching and burning.

Risk in Pregnancy

TO

Adverse effects

Dry skin and local irritation due to hypersensitivity.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug.
Precautions: Avoid using soaps after applying the bath.

Interactions

None of clinical importance.

BENZYL

Clue	Description	Indications	Route of administration and dosage
	DERMAL EMULSION	Scabies.	Cutaneous.

010.000.0861.00	Each mL contains: Benzyl benzoate 300 mg. Container with 120 mL.	Pediculosis.	Adults and children: Application for three consecutive nights; Bath the next morning with a change of clothes. Repeat at the doctor's discretion.

Generalities

It acts against *Pediculus capitis* and pubis, as well as against *Sarcoptes scabiei.*

Risk in Pregnancy b

Adverse effects

Burning, itching, contact dermatitis.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug.
Precautions: Skin burns or extensive abrasions, do not apply to the face, apply with caution to children.

Interactions

None of clinical importance.

BENZOYL

Clue	Description	Indications	Route of administration and dosage
010.000.0822.00 010.000.0822.01 010.000.0822.02	DERMAL LOTION OR GEL DERMAL Every 100 milliliters or grams contain: Benzoyl peroxide 5 g. Container with 30 mL. Container with 50 mL. Container with 60 g.	Acne vulgaris. Antiseborrheic.	Cutaneous. Adults and kids older than 12 years old: After cleaning, apply to the areas affected, for two hours and wash immediately for 4 days. Subsequently, apply daily before going to bed and leave overnight for 7 more days.

Generalities

Oxidizing agent that provides bactericidal, keratolytic, sebostatic and anti-inflammatory action.

Risk in Pregnancy b

Adverse effects

Erythema, skin irritation and contact dermatitis.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug.
Precautions: Inflamed or injured skin, avoid contact with eyes, neck, perioral area, mucous membranes as well as exposure to sunlight.

Interactions

Its use with other anti-acne agents or exfoliating agent preparations is not recommended due to excessive skin irritation.

CLIOQUINOL

Clue	Description	Indications	Route of administration and dosage
010.000.0872.00	CREAM Each g contains: Clioquinol 30 mg. Container with 20 g.	Dermatomycosis. Infectious dermatitis.	Cutaneous. Adults and children: Apply in a thin layer every 12 to 24 hours, for 7 days.

Generalities

Drug with bacteriostatic and fungicidal activity.

Risk in Pregnancy

b

Adverse effects

Local irritation, burning, pruritus, contact dermatitis.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug. Children under two years of age.
Precautions: Application to relatively large or eroded areas and mucous membranes, as well as treatment for more than a week.

Interactions

None of clinical importance.

DUPILUMAB ***(In Catalog II program)***

Clue	Description	Indications	Route of administration and dosage
010.000.7003.00	INJECTABLE SOLUTION Each prefilled syringe contains: Dupilumab 300 mg Box with 2 prefilled syringes with 300 mg/ 2ml with needle protector and attached instructions	Treatment of patients 12 years of age and older with severe atopic dermatitis, whose disease is not adequately controlled by topical prescription therapies or when such therapies are not recommended. Can be used or without topical therapy (topical corticosteroids) with	Subcutaneous injection Adults. An initial dose of 600 mg (two 300 mg injections), followed by 300 mg given every other weeks. Teenagers For adolescent patients from 12 to 17 years old with a body weight greater than 60 kg. An initial dose of 600 mg (two 300 mg injections), followed by 300 mg given every two weeks.
010.000.7003.01	INJECTABLE SOLUTION Each prefilled syringe contains: Dupilumab 200 mg Box with 2 prefilled syringes with 200 mg/ 1.14 mL with needle protector and attached instructions		For adolescent patients from 12 to 17 years old with a body weight less than 60 kg. An initial dose of 400 mg (two 200 mg injections), followed by 200 mg given every other weeks.

Generalities

Dupilumab is an antagonist of interleukin 4 alpha receptors, it is a human monoclonal antibody of the IgG4 subclass that binds to the IL-R subunit and inhibits IL-4 and IL-13 signaling. Dupilumab has an approximate molecular weight of 147 kDa. Dupilumab is produced by recombinant DNA technology, in the suspension culture of Chinese Hamster Ovary cells.

Risk in Pregnancy

c

Adverse effects

The most frequent adverse events were mild and moderate: Irritation at the temporary application site, conjunctivitis and oral herpes.

Contraindications and Precautions

Hypersensitivity to any of the components of the formula, pregnancy, lactation, active parasitic infections, children under 12 years of age.

Interactions

Avoid the use of live vaccines in patients treated with dupilumab.

FLUOCINOLONE

Clue	Description	Indications	Route of administration and dosage
010.000.0811.00	CREAM Each g contains: Fluocinolone acetonide 0.1 mg. Container with 20 g.	Acute dermatitis infected.	Cutaneous. Adults: Apply every 12 to 24 hours.

Generalities

It diffuses through the cell membrane and binds with specific intracellular receptors to produce its anti-inflammatory effect.

Risk in Pregnancy b

Adverse effects

Burning, itching, irritation, dryness, hypopigmentation, skin atrophy, rosaceiform dermatitis and hypertrichosis.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug, cutaneous tuberculosis, pyodermitis, herpes simplex, superficial mycoses and chickenpox.

Interactions

None of clinical importance.

HYDROCORTISONE

Clue	Description	Indications	Route of administration and dosage
010.000.0813.00	CREAM Each g contains: 17 Hydrocortisone butyrate 1 mg. Container with 15 g.	Acute dermatitis infected.	Cutaneous. Adults and children: Apply every 8 to 24 hours.

Generalities

It diffuses across the cell membrane and forms complexes with specific intracellular receptors.

Risk in Pregnancy b

Adverse effects

Burning, itching, irritation and skin atrophy.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug. Skin infections, Eczema.

Interactions

With other corticosteroids, adverse effects increase.

HYDROQUINONE

Clue	Description	Indications	Route of administration and dosage
010.000.4134.01	CREAM Each 100 grams contain: Hydroquinone 4.0 g. Container with 30 g.	Chloasma.	Cutaneous. Adults: It should be applied to the affected areas, exclusively at night.

Generalities

Topical demelanizer that depletes deposits and prevents melanin synthesis, without destroying melanocytes or producing permanent depigmentation.

Risk in Pregnancy

b

Adverse effects

Moderate skin irritation, burning and allergic dermatitis.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug.
Precautions: You should not expose yourself to the sun after applying the medicine.

Interactions

None of clinical importance.

ISOCONAZOLE

Clue	Description	Indications	Route of administration and dosage
010.000.2024.00	CREAM Each 100 grams contains: Isoconazole Nitrate 1 g. Container with 20 g.	Dermatomycosis	Cutaneous. Adults: Apply every 24 hours.

Generalities

Broad-spectrum antifungal, which inhibits the synthesis of the fungal membrane.

Risk in Pregnancy

b

Adverse effects

Skin irritations, allergic skin reactions.

Contraindications and precautions

Contraindications: Hypersensitivity to the drug.

Interactions

None of clinical importance.

MICONAZOLE

Clue	Description	Indications	Route of administration and dosage
010.000.0891.00	CREAM Each gram contains: Miconazole nitrate 20 mg. Container with 20 g.	Cutaneous mycoses	Cutaneous. Adults and children: Apply every 12 hours, morning and night, for six weeks.

Generalities

It acts on the fungal membrane and inhibits the synthesis of ergosterol and other sterols, with the consequent alteration of permeability and loss of essential cellular elements.

Risk in Pregnancy

b

Adverse effects

Contact dermatitis.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug.
Precautions: Avoid sealing the application on the skin and use in intertriginous areas.

Interactions

None of clinical importance.

MOMETASONE

Clue	Description	Indications	Route of administration and dosage
010.000.4132.00	OINTMENT Each 100 grams contain: Mometasone furoate 0.100 g. Container with 30 g.	Seborrheic eczema. Atopic or contact dermatitis. Psoriasis.	Cutaneous. Adults: A single application every 24 hours, for a short period of 2-3 weeks.
010.000.4133.01	LOTION Every 100 milliliter contains: Mometasone furoate 0.100 g. Container with 60 mL.		

Generalities

Topical corticosteroid with anti-inflammatory and antipruritic effects, which is metabolized in the liver and excreted through the kidneys.

Risk in Pregnancy

b

Adverse effects

Dermatitis, pruritus and skin atrophy.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug, do not apply to infected areas.
Precautions: Do not use around the eyes.

Interactions

None of clinical importance.

ZINC OXIDE

Clue	Description	Indications	Route of administration and dosage
010.000.0804.00	PASTA Each 100 g contains: Zinc oxide 25.0 g. Container with 30 g.	Skin disease.	Cutaneous. Adults and children: Apply a thin layer every 6 to 24 hours.

Generalities

It exerts a protective astringent and antiseptic action on the skin.

Risk in Pregnancy

TO

Adverse effects

Erythema.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug.

Interactions

None of clinical importance.

PERMETHRIN

Clue	Description	Indications	Route of administration and dosage
	SOLUTION	Pediculosis	Topical.

010.000.0865.00	Each 100 mL contains: Permethrin 1 g. Container with 110 mL.		Adults and children over two years of age: Apply 30 mL of solution to previously moistened hair until foaming, leave it to act for 10 minutes and rinse with plenty of water, then dry your hair with a towel. If necessary, its application can be repeated 5 days later.

Generalities

Synthetic pyrethroid with insecticidal action against *Pediculus capitis, corporis and pubis.* Effect on both adult parasites and eggs (nits). It acts as a neurotoxin that depolarizes the nerve cell membrane of the parasite, breaking down sodium channels. Delayed depolarization produces paralysis of the respiratory exoskeletal muscles and death of the parasite. The residual effect on the hair is approximately 2 weeks.

Risk in Pregnancy

C

Adverse effects

Local irritative manifestations such as burning, pruritus and erythema. Overdose produces dryness, cracking of the skin and manifestations of skin hypersensitivity.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug or any other component of the medication.
Precautions: Do not apply to children under 2 months old or to patients with a history of seizures.
Do not apply on burns or skin wounds.

Interactions

None of clinical importance.

PODOPHYLLIN

Clue	Description	Indications	Route of administration and dosage
010.000.0901.00	DERMAL SOLUTION Each mL contains: Podophyllin resin 250 mg. Container with 5 mL.	Condyloma acuminata. Seborrheic warts.	Cutaneous. Adults and children: Before applying the medicine, cover the skin with Lassar paste (zinc oxide). circumneighbor. Apply the medicine with a swab on the lesion and leave it for 4 to 5 hours. Then wash with soap and water to remove it. Repeat the procedure at the doctor's discretion.

Generalities

Keratolytic action that causes peeling of the cornified epithelium.

Risk in Pregnancy

C

Adverse effects

Irritation and burning of the adjacent skin.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug.
Precautions: Do not apply to mucous membranes or near the eyes.

Interactions

None of clinical importance.

RETINOIC ACID

Clue	Description	Indications	Route of administration and dosage
010.000.0904.00	CREAM Each 100 grams contain: Retinoic acid 0.05 g. Container with 20 g.	Acne. Heliodermatitis. Hyperkeratosis. Hyperchromia.	Cutaneous. Adults and children: Apply directly at night, for three months, after cleaning the area.

Generalities

It stimulates mitosis and the turnover of epidermal cells and activates the repair of connective tissue.

Risk in Pregnancy

TO

Adverse effects

Local heat, burning and erythema, exfoliation, hyperpigmentation or temporary hypopigmentation.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug. Do not apply to sunburns.

Interactions

Applying medications with alcohol or menthol can increase the risk of hives. Assess the application of keratolytics.

ANTHRALIN

Clue	Description	Indications	Route of administration and dosage
010.000.5130.00	OINTMENT Each g contains: Anthralin 20 mg. Container with 50 g.	Psoriasis.	Cutaneous. Adults: Apply to lesion plates psoriatic with a light massage, leave for 10 to 30 minutes and remove with a facial tissue.

Generalities

Its exact mechanism of action is not known; it is believed that there is an interaction of DNA, especially with DNA. mitochondrial.

Risk in Pregnancy

TO

Adverse effects

Irritation to adjacent healthy skin.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug. Do not use in pustular psoriasis.
Precautions: Do not apply to the face, genitals, inner thighs or skin folds.

Interactions

None of clinical importance.

BETAMETHASONE

Clue	Description	Indications	Route of administration and dosage
	OINTMENT Each 100 grams contains: Betamethasone dipropionate 64 mg equivalent to 50 mg of	Acute dermatoses. Acute, atopic or contact dermatitis, not complicated or infected.	Cutaneous. Adults and children: Apply every 24 hours, for 1 to 5 days,

010.000.2119.00	betamethasone. Container with 30 g.		after cleaning the affected area.

Generalities

It stimulates the transcription of RNA, with an increase in the protein synthesis of enzymes responsible for its anti-inflammatory effects.

Risk in Pregnancy b

Adverse effects

Infection, atrophy, stretch marks, miliary rash and burning.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug, skin infections and eczema.

Interactions

With other topical corticosteroids, their adverse effects increase.

CALCIPOTRIOL, BETAMETHASONE

Clue	Description	Indications	Route of administration and dosage
010.000.5612.00	OINTMENT Each 100 g contains: Calcipotriol 5 mg. Betamethasone dipropionate equivalent to 50 mg betamethasone Container with 30 g.	Treatment of psoriasis mild to moderate vulgarity.	Cutaneous. Adults: Apply to lesions once a day, without exceeding a total dose of 100 g per week, for a maximum of 4 weeks.

Generalities

Calcipotriol is a potent inhibitor of epidermal proliferation and regulator of cell differentiation. At the tissue level, the action of calcipotriol is very similar to that observed with calcitriol (1,25-[OH]2D3), while the systemic effects at the calcium level are at least 100 to 200 times smaller. The affinity of calcipotriol for receptors of vitamin D is as high as that of calcitriol.

Betamethasone dipropionate is absorbed from healthy or diseased skin. When the skin is inflamed, it can increase the percutaneous absorption of any substance. The actions of betamethasone dipropionate occur inside the cell, where it binds to specific receptors. Once bound to the receptor, they migrate towards the nucleus and in the DNA they cause an anti-inflammatory, antiproliferative and immunosuppressive response. Betamethasone dipropionate penetrates the epidermis and forms a reservoir, which allows for prolonged action. Apparently small amounts reach the dermis and therefore the blood circulation. Once in the blood circulation, it binds reversibly to plasma proteins, and is metabolized both at the hepatic and extrahepatic levels, resulting in mostly inactive metabolites. After 72 hours they are almost completely excreted through the kidneys.

Risk in Pregnancy c

Adverse effects

Itching, irritation, erythema or worsening of psoriasis locally and temporarily. Other manifestations that occur with steroid use include folliculitis, hypertrichosis, perioral dermatitis, allergic contact dermatitis, and depigmentation.

Long-term steroid use can result in skin atrophy, telangiectasias, and stretch marks.

Contraindications and Precautions

Contraindications: Hypersensitivity to drugs.
Precautions: Should not be used in patients with known calcium metabolism disorders. It should not be used in cases of bacterial infection or skin candidiasis, in which case they must be resolved before starting treatment with Calcipotriol, Betamethasone.

Interactions

They have not been reported to date.

RECOMBINANT HUMAN EPIDERMAL GROWTH FACTOR (HREF)

Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION Each vial with lyophilisate contains: Growth factor Human Epidermal 0.075 mg	Adjuvant in others conventional therapies for the management of the diabetic foot to stimulate the formation of granulation tissue in patients with neuropathic and ischemic ulcers, in stages	Parenteral, intralesionally. Adults Administer at a rate of 0.075 mg diluted in 5 mL of water for injection, 3 times a week intralesionally. The administrations will be continued until complete granulation of the lesion is achieved, its closure by grafting or a maximum of 8 weeks of treatment is reached.
010.000.6156.00	Container with 6 vials with freeze-dried.	3 and 4 of the Warner classification with an area	
010.000.6156.01	Container with 1 vial with freeze-dried.	greater than 1 cm2 , with minimal trophic conditions, absence of infection and inflammation and in adequate metabolic control and comorbid states.	

Generalities

Human recombinant epidermal growth factor (rhGF) is a molecule of recombinant DNA origin expressed in Saccharomyces cerevisiae SEY 2202 cells. It regulates the growth, differentiation and metabolism of various cells. Stimulates the migration and proliferation of fibroblasts that allow the synthesis and deposition of collagen.
It exerts its action by binding to a specific receptor located on the membrane of target cells. The receptor is a glycoprotein with tyrosine kinase activity.

Risk in Pregnancy

c

Adverse effects

Pain and burning at the application site, chills, chills, local infection and fever.

Contraindications and Precautions

Contraindications: Hypersensitivity to the biological.
Precautions: In patients with acute cardiovascular events such as: acute myocardial infarction, stroke or transient ischemia or thromboembolism; as well as patients with clinically relevant valvular disease, such as: calcified aortic valves; severe arterial hypertension and history of venous thrombosis.

Interactions

There are no known interactions with other topical medications. That is why it is recommended not to apply it with other topical products.

FLUOROURACIL

Clue	Description	Indications	Route of administration and dosage
	CREAM OR OINTMENT Each gram contains: 5- Fluorouracil 50 mg.	Actinic keratosis.	Cutaneous. Adults and children: Apply every 12 hours, in sufficient quantity to cover the lesion, without transferring to healthy skin.
010.000.0903.00	Container with 20 g.		

Generalities

Specific antimetabolite of the “S” phase of the cell cycle. Inhibits DNA synthesis which causes growth unbalanced that is not compatible with cellular life so it dies.

Risk in Pregnancy

d

Adverse effects

Skin irritation, phototoxicity, erythema, edema, pruritus, darkening and hardening of the skin in application areas.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug.

Precautions: Avoid contact with mucous membranes and exposure to sunlight.

Interactions

None of clinical importance.

IMIQUIMOD

Clue	Description	Indications	Route of administration and dosage
010.000.4140.00	5% CREAM Each sachet contains: Imiquimod 12.5 mg. Package with 12 sachets, containing 250 mg of cream.	Genital warts and perianal (condyloma acuminata). Actinic keratosis. Basal cell carcinoma superficial.	Cutaneous Adults: Genital warts: Apply a thin layer of cream, three times a week, before going to bed. Maximum duration of treatment 16 weeks. Actinic keratosis: Apply a thin layer of cream, twice a week, before going to bed. Maximum duration of treatment 16 weeks. Superficial basal cell carcinoma: Apply a thin layer of cream, five times a week, before going to bed, for 6 consecutive weeks.

Generalities

It is a heterocyclic amine and midazoquinoline with a topical immune response-modifying effect; It exerts antiviral and antitumor activity mediated by the synthesis of cytokines.

Risk in Pregnancy

b

Adverse effects

Itching, burning and local pain.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug.
Precautions: Avoid contact with eyes and do not cover the treated area.

Interactions

None of clinical importance.

ISOTRETINOIN

Clue	Description	Indications	Route of administration and dosage
040.000.4129.00	CAPSULE Each capsule contains: Isotretinoin 20 mg. Container with 30 capsules.	Severe acne.	Oral. Adults and adolescents: 0.5 to 2 mg/kg body weight/day, each 12 to 24 hours.

Generalities

Synthetic analogue of vitamin A, which acts by reducing the activity and size of the sebaceous glands.

Risk in Pregnancy

x

Adverse effects

Dryness, itching and peeling of the skin; dryness, pain, inflammation and bleeding of mucous membranes; visual problems due to dryness, pruritus and conjunctival hyperemia; depression and mood changes.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug. Pregnancy.
Precautions: Do not use in women of childbearing age and with an active sexual life. Liver or kidney failure. Hypervitaminosis A. Hyperlipidemias.

Interactions

Carbamazepine, tetracyclines, vitamin A and ethanol increase irritative phenomena.

IXEKIZUMAB

Clue	Description	Indications	Route of administration and dosage
010.000.6178.00	INJECTABLE SOLUTION Each pre-filled pen contains: Ixekizumab 80 mg Package with a pen prefilled with 1 mL of solution (80 mg/mL).	Plaque psoriasis, moderate to severe, in adults who are candidates for are systemic therapy or phototherapy.	Subcutaneous. Adults: 160 mg at week 0, followed by 80 mg at weeks 2,4, 6, 8, 10, and 12, followed by a maintenance dose of 80 mg every 4 weeks.

Generalities

Ixekizumab is an IgG4 monoclonal antibody that binds with high affinity (<3 pM) and specifically to interleukin 17A (both IL-17A and IL-17A/F), a pro-inflammatory interleukin.

Risk in Pregnancy

c

Adverse effects

Upper respiratory tract infection, ringworm infection, oropharyngeal pain, nausea, injection site reactions.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug
Precautions: Treatment with ixekizumab is associated with an increased rate of infections such as upper respiratory tract infections, oral candidiasis, conjunctivitis, and ringworm infections. Ixekizumab should not be administered to patients with active tuberculosis (TB). Treatment should be considered

antituberculous drug before starting treatment with ixekizumab in patients with latent TB. have been reported
new cases or exacerbations of Crohn's disease and ulcerative colitis. Caution should be used when prescribing ixekizumab to patients with inflammatory bowel disease, including Crohn's disease and ulcerative colitis, and patients should be closely monitored. Ixekizumab should not be administered simultaneously with live vaccines. There are insufficient data available on the response to live vaccines or inactivated vaccines.

Interactions

The role of IL-17 in the regulation of CYP450 enzymes has not been documented. However, the formation of some CYP450 enzymes is suppressed by an increase in cytokine levels during chronic inflammation. Therefore, anti-inflammatory treatments such as ixekizumab, an IL17A inhibitor, could normalize CYP450 levels and consequently decrease exposure to concomitant medications metabolized by CYP450.
Therefore, it cannot be excluded that there is a relevant clinical effect on drugs with a narrow therapeutic range that are CYP450 substrates, where the dose is adjusted individually (e.g. warfarin).

METHOXALENE

Clue	Description	Indications	Route of administration and dosage
010.000.5126.00	CAPSULE OR TABLET Each capsule or tablet contains: Methoxalene 10 mg. Package with 30 capsules or tablets.	Psoriasis. Vitiligo.	Oral. Adults: 0.6 mg/kg body weight, one or two hours before exposure to ultraviolet rays.

Generalities

Psoralen with photosensitizing activity, for repigmentation requires the presence of active melanocytes.

Risk in Pregnancy

c

Adverse effects

Photosensitivity, dizziness, headache and nausea.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug, diseases associated with photosensitivity and skin cancer.
Precautions: Avoid exposure to sunlight after ultraviolet light treatment.

Interactions

Photosensitizing drugs can produce additive effects.

MUPIROCIN

Clue	Description	Indications	Route of administration and dosage
010.000.2123.00	OINTMENT Each 100 grams contains: Mupirocin 2 g. Container with 15 g.	Infectious dermatitis.	Cutaneous. Adults: One application every 8 hours The duration depends on the specialist doctor, usually it is 5 to 10 days.

Generalities

Broad-spectrum topical antibiotic that inhibits protein synthesis by binding to the isoleucyl RNA transfer enzyme in bacteria.

Risk in Pregnancy

NE

Adverse effects

Pruritus and erythema.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug, Fungal or viral infections.
Precautions: Should not be applied near the eyes or mucous membranes.

Interactions

None of clinical importance.

PIMECROLIMUS

Clue	Description	Indications	Route of administration and dosage
010.000.4131.00 010.000.4131.01	CREAM Each 100 g contains: Pimecrolimus 1 g. Container with 15 g. Container with 30 g.	Atopic dermatitis.	Cutaneous. Adults: Apply a thin layer to affected skin every 12 hours. Children 3 months and older: Apply a thin layer to affected skin every 12 hours.

Generalities

Ascomycin-derived macrolactam anti-inflammatory and selective inhibitor of the production and release of proinflammatory cytokines and mediators from T cells and mast cells. It binds with high affinity to macrophilin 12 and inhibits the calcium-dependent phosphatase calcineurin. It therefore inhibits T cell activation by blocking the transcription of early cytokines.

Risk in Pregnancy

TO

Adverse effects

Common: Sensation of heat or burning at the application site. Common: Irritation, pruritus and erythema; skin infections. Uncommon: Impetigo, aggravation of the condition, herpes simplex, eczema *herpeticum,* molluscum contagiosum, changes at the application site such as rash, pain, paresthesia, peeling, dryness, edema, skin papilloma and boil.

Contraindications and Precautions

Contraindications: Hypersensitivity to the medication or any of the excipients.
Precautions: Do not apply to areas with acute viral infections. In the event of a bacterial or fungal infection, the appropriate antimicrobial should be indicated. If the infection does not resolve, the medication should be discontinued until the infection has been controlled.

Interactions

None of clinical importance.

SECUKINUMAB

Clue	Description	Indications	Route of administration and dosage
010.000.6080.00	INJECTABLE SOLUTION Each pre-filled pen contains: Secukinumab 150 mg Package with two pre-filled pens with 1 mL (150 mg/mL).	Plaque psoriasis in moderate to severe in patients candidates that are for systemic biological therapy. Active psoriatic arthritis, alone or in combination with methotrexate.	Subcutaneous. Adults: Plaque psoriasis: 300 mg by subcutaneous injection with an initial dose at weeks 0, 1, 2 and 3 followed by monthly maintenance doses starting at week 4. Active psoriatic arthritis: 150 mg by subcutaneous injection, administered initially on weeks 0, 1, 2 and 3 and then from week 4 on a monthly basis.

Generalities

Secukinumab is a fully human IgG1 monoclonal antibody that selectively binds and neutralizes the proinflammatory cytokine IL-17A. Secukinmab inhibits the interaction of IL-17A with the IL-17 receptor, which is expressed on various cell types including keratinocytes.

Risk in Pregnancy

b

Adverse effects

Rhinopharyngitis, Pharyngitis, Rhinitis, Sinusitis, Tonsillitis, Oral herpes, Oral candidiasis, Neutropenia, Conjunctivitis, Diarrhea, Tinea pedis, Otitis externa.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug.

Precautions: Infections: Mild to moderate upper respiratory tract such as nasopharyngitis without the need to interrupt treatment. Mucocutaneous infections due to Candida. Crohn's disease: Exacerbations of the disease, in some cases severe, have been observed in patients with active Crohn's disease. Vaccines: Live vaccines should not be administered simultaneously with secukinumab.

Interactions

Live vaccines should not be administered simultaneously with Secukinumab. The formation of some CYP450 enzymes is suppressed by increased cytokine levels during chronic inflammation. Therefore a clinically significant effect on CYP450 substrates cannot be excluded as a narrow therapeutic index, where the dose is individually adjusted (e.g. warfarin). Secukinumab has been administered with methotrexate and/or corticosteroids in arthritis studies (including psoriatic arthritis and ankylosing spondylitis) in which no interaction was observed.

SILVER SULFADIAZINE

Clue	Description	Indications	Route of administration and dosage
010.000.4126.00	CREAM Each 100 grams contains: Micronized silver sulfadiazine 1 g. Container with 375 g.	Adjuvant in prevention and treatment of sepsis in second- and third-degree burn injuries.	Cutaneous. Adults: Apply every 12 hours, in an approximate thickness of 1.6 mm. Duration of treatment at the discretion of the specialist, 1-2 weeks.

Generalities

Broad spectrum antimicrobial that includes the most common germs in burns.

Risk in Pregnancy

d

Adverse effects

Rash, itching, burning sensation.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug and in neonates.
Precautions: Keep the application area covered and liver or kidney failure.

Interactions

None of clinical importance.

USTEKINUMAB

Clue	Description	Indications	Route of administration and dosage
010.000.5695.00 010.000.5695.01	INJECTABLE SOLUTION Each vial contains: Ustekinumab 45 mg. Container with a vial bottle with 0.5 mL. Package with a prefilled syringe with 0.5 mL.	Treatment of psoriasis in moderate to severe plaque in adults, who do not respond to, are contraindicated or do not tolerate other systemic therapies, including cyclosporine, methotrexate and PUVA; It can also be used in patients refractory to other biological agents.	Subcutaneous. Adults: 45 mg initially, followed by another dose of 45 mg 4 weeks later and every 12 weeks thereafter.

Generalities

Ustekinumab is a fully human IgG1ÿ monoclonal antibody that binds with high affinity and specificity to the p40 protein subunit of the human cytokines IL-12 and IL-23. Ustekinumab inhibits the activity of human IL-12 and IL-23 by preventing the binding of these cytokines to their receptor protein IL-12R ÿ 1, expressed on the surface of immune cells.

Risk in pregnancy C

Adverse effects

Upper respiratory tract infection, nasopharyngitis, cellulitis, upper respiratory tract viral infection, hypersensitivity reactions (including rash, urticaria), depression, dizziness, headache, pharyngolaryngeal pain, nasal congestion, diarrhea, pruritus, back pain, myalgia, arthralgia, fatigue, erythema at the injection site.

Contraindications and precautions

Contraindications: Hypersensitivity to the drug. Clinically significant active infections (e.g. active tuberculosis).
Precautions: Ustekinumab may increase the risk of infections and reactivate latent infections. Immunosuppressants such as ustekinumab may increase the risk of malignant tumors. It is recommended not to administer live virus or live bacterial vaccines.

Interactions

Live attenuated vaccines should not be administered at the same time as Ustekinumab. The safety and effectiveness of Ustekinumab in combination with other immunosuppressants, including biologics, or phototherapy have not been evaluated.